Please provide your email address to receive an email when new articles are posted on . Patients taking colchicine had a weighted hazard ratio of 0.82 (95% CI, 0.69-0.94) for cardiovascular events.

Patients with gout are commonly prescribed colchicine prophylaxis, despite already taking medications that could potentially interact. Patients with gout are commonly prescribed colchicine prophylaxis ...

Please provide your email address to receive an email when new articles are posted on . More than 25% of patients with gout who use colchicine prophylaxis were on potentially interacting medications.

New research indicates that a drug commonly prescribed for gout may also lower the risk of heart attack and stroke when taken at an appropriate dose.Researchers from the UK, Sweden and Italy analysed ...

Gout patients who take colchicine at the start of urate-lowering therapy have a lower risk for cardiovascular events than those who do not receive prophylaxis. The risk for cardiovascular events was ...

Matched cohort studies revealed infrequent adverse events (AEs) with either treatment, but the number needed to harm for any AE was more than three times higher with colchicine vs NSAIDs. The ...

In recent years, scientists have increasingly turned their attention to older, affordable drugs to explore whether they offer benefits beyond their original purpose. Colchicine, a cheap and widely ...

Due to a policy decision in 2010 by the U.S. Food and Drug Administration (FDA), the price of a prescription for the therapeutic gout drug colchicine increased nearly 16-fold from $11.25 in 2009 to ...

(Boston)—Gout is the most common form of inflammatory arthritis, with worldwide prevalence of approximately four%. The accumulation of monosodium urate crystals in gout leads to the clinical ...

Scilex Holding Company announced an amendment to its license agreement with Romeg Therapeutics for Gloperba®, the first and only liquid oral formulation of colchicine, indicated for preventing painful ...

Colchicine may be used with caution to manage flare-ups of crystal-induced arthritis among patients with severe chronic kidney disease, with dosage modifications and careful monitoring required.

The media reports that colchicine, a very old drug, has now been discovered to reduce the risk of recurrent heart disease and has a new FDA indication. Of course, the “discovery” has taken 10 years, ...